Biologically Active Small Molecules

A potent, selective CysLT2 receptor antagonist that inhibits radioligand binding of LTD4 to CysLT2 and CysLT1 receptor cell lines with IC50 values of 35 and &gt10,000 nM, respectively.

A potent, selective CysLT2 receptor antagonist that inhibits radioligand binding of LTD4 to CysLT2 and CysLT1 receptor cell lines with IC50 values of 35 and &gt10,000 nM, respectively.

A selective inhibitor of BAZ2A (Kd = 109 nM IC₅₀ = 130 nM) and BAZ2B (Kd = 170 nM IC₅₀ = 180 nM) bromodomains.

A selective inhibitor of BAZ2A (Kd = 109 nM IC₅₀ = 130 nM) and BAZ2B (Kd = 170 nM IC₅₀ = 180 nM) bromodomains.

A selective inhibitor of BAZ2A (Kd = 109 nM IC₅₀ = 130 nM) and BAZ2B (Kd = 170 nM IC₅₀ = 180 nM) bromodomains.

A selective inhibitor of BAZ2A (Kd = 109 nM IC₅₀ = 130 nM) and BAZ2B (Kd = 170 nM IC₅₀ = 180 nM) bromodomains.

An indole-based SERM that binds to both ER&alpha (IC₅₀ = 26 nM) and ER&beta (IC₅₀ = 99 nM) antagonizes 17&beta-estradiol-dependent and hormone-independent growth of breast cancer cell proliferation (80% reduction with 10

An indole-based SERM that binds to both ER&alpha (IC₅₀ = 26 nM) and ER&beta (IC₅₀ = 99 nM) antagonizes 17&beta-estradiol-dependent and hormone-independent growth of breast cancer cell proliferation (80% reduction with 10

An indole-based SERM that binds to both ER&alpha (IC₅₀ = 26 nM) and ER&beta (IC₅₀ = 99 nM) antagonizes 17&beta-estradiol-dependent and hormone-independent growth of breast cancer cell proliferation (80% reduction with 10

An indole-based SERM that binds to both ER&alpha (IC₅₀ = 26 nM) and ER&beta (IC₅₀ = 99 nM) antagonizes 17&beta-estradiol-dependent and hormone-independent growth of breast cancer cell proliferation (80% reduction with 10

A Cl-amidine derivative with greater cellular potency against PAD4 activity (EC₅₀ = 8.8 &microM, vs.

A Cl-amidine derivative with greater cellular potency against PAD4 activity (EC₅₀ = 8.8 &microM, vs.